Suppr超能文献

肾盂肉瘤样尿路上皮癌行免疫治疗。

Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.

机构信息

Department of Urology, Niigata City General Hospital, 463-7 Shumoku, Chuo-ku, Niigata-City, Niigata, 950-1197, Japan.

Department of Pathology, Niigata City General Hospital, Niigata, Japan.

出版信息

BMC Urol. 2023 Mar 18;23(1):38. doi: 10.1186/s12894-023-01210-z.

Abstract

BACKGROUND

Sarcomatoid carcinoma is a rare, high-grade malignancy with epithelial and mesenchymal components. It may be a good candidate for immunotherapy because it is associated with overexpression of programmed cell death ligand 1. Sarcomatoid urothelial carcinoma (UC) of the upper urinary tract is extremely rare. Here we report the first case of sarcomatoid UC of the renal pelvis that responded to immunotherapy.

CASE PRESENTATION

A 79-year-old man was referred to our hospital complaining of various symptoms, including anorexia and abdominal pain. A computed tomography scan revealed a right atrial tumor, a 9 cm left renal mass with a renal vein tumor thrombus, para-aortic lymphadenopathy, and multiple small lung nodules. The patient underwent resection of the right atrial tumor. Pathological analysis of the tumor did not lead to an accurate diagnosis even after several rounds of immunohistochemistry. He underwent a needle biopsy of the left kidney and was initially diagnosed with collecting duct carcinoma, a rare subtype of renal cell carcinoma (RCC). Following the initial diagnosis, immunotherapy with nivolumab and ipilimumab commenced. Thereafter, almost all lesions, including the left renal tumor, were reduced in size. However, he underwent a left nephrectomy approximately a year after beginning immunotherapy due to repeated left renal bleeding. Histological examination of the nephrectomy specimen revealed two forms of cancer-sarcomatoid UC and conventional high-grade UC. Two months after surgery, the patient was found to have new lung metastases. He underwent chemotherapy with gemcitabine and cisplatin, followed by immunotherapy with pembrolizumab. However, both treatments were ineffective. The patient died of cancer 19 months after his first admission.

CONCLUSIONS

The presented case of sarcomatoid UC of the renal pelvis that partially responded to immunotherapy suggests that immunotherapy can be a promising treatment for sarcomatoid UC.

摘要

背景

梭形细胞癌是一种罕见的高级别恶性肿瘤,具有上皮和间叶成分。它可能是免疫治疗的一个很好的候选者,因为它与程序性细胞死亡配体 1 的过度表达有关。上尿路的梭形尿路上皮癌(UC)极为罕见。在此,我们报告首例肾盂梭形 UC 对免疫治疗有反应的病例。

病例介绍

一名 79 岁男性因多种症状(包括厌食和腹痛)被转诊至我院。计算机断层扫描显示右心房肿瘤、左肾 9 cm 大的肿块伴肾静脉肿瘤栓、主动脉旁淋巴结肿大和多个小结节。患者接受了右心房肿瘤切除术。即使经过几轮免疫组织化学检查,肿瘤的病理分析也未能得出准确的诊断。他接受了左肾的活检,最初诊断为罕见的肾细胞癌(RCC)亚型——集合管癌。初始诊断后,开始用纳武单抗和伊匹单抗进行免疫治疗。此后,包括左肾肿瘤在内的几乎所有病变都缩小了。然而,大约在免疫治疗开始一年后,由于左肾反复出血,他接受了左肾切除术。左肾切除术标本的组织学检查显示两种形式的癌症——梭形 UC 和常规高级 UC。手术后两个月,患者发现有新的肺转移。他接受了吉西他滨和顺铂化疗,随后接受了 pembrolizumab 免疫治疗。然而,两种治疗均无效。患者在首次入院后 19 个月因癌症去世。

结论

本例肾盂梭形 UC 部分对免疫治疗有反应,提示免疫治疗可能是梭形 UC 的一种有前途的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9464/10024438/04e89a33f42f/12894_2023_1210_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验